Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the SQ Tree Sublingual Immunotherapy Tablet in Children and Adolescents With Moderate to Severe Allergic Rhinitis and/or Conjunctivitis Induced by Pollen From Birch and Trees Belonging to the Birch Homologous Group

NCT04878354 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT04878354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04878354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the SQ Tree Sublingual Immunotherapy Tablet in Children and Adolescents With Moderate to Severe Allergic Rhinitis and/or Conjunctivitis Induced by Pollen From Birch and Trees Belonging to the Birch Homologous Group
Lead sponsor
ALK-Abelló A/S
Phase
Phase 3
Overall status
Completed
Start date
April 7, 2021
Completion date
July 31, 2023
Enrollment
952 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

allergy